Oral Porphyromonas gingivalis translocates to the liver and regulates hepatic glycogen synthesis through the Akt/GSK-3β signaling pathway  by Ishikawa, Makoto et al.
Biochimica et Biophysica Acta 1832 (2013) 2035–2043
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isOral Porphyromonas gingivalis translocates to the liver and regulates
hepatic glycogen synthesis through the Akt/GSK-3β signaling pathwayMakoto Ishikawa a, Kaya Yoshida b,⁎, Hirohiko Okamura c, Kazuhiko Ochiai d, Haruna Takamura a,
Natsumi Fujiwara a, Kazumi Ozaki a
a Department of Oral Healthcare Promotion, The University of Tokushima Graduate School, Kuramoto, Tokushima 770-8504, Japan
b Department of Oral Healthcare Education, The University of Tokushima Graduate School, Kuramoto, Tokushima 770-8504, Japan
c Department of Histology and Oral Histology, Institute of Health Biosciences, The University of Tokushima Graduate School, Kuramoto, Tokushima 770-8504, Japan
d Department of Basic Science, School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonan, Musashino, Tokyo 180-
8602, Japan⁎ Corresponding author at: 3-18-15, Kuramoto, Tokus
+81 88 633 7898.
E-mail address: kaya@tokushima-u.ac.jp (K. Yoshida).
0925-4439/$ – see front matter © 2013 Elsevier B.V. All r
http://dx.doi.org/10.1016/j.bbadis.2013.07.012a b s t r a c ta r t i c l e i n f oArticle history:
Received 4 March 2013
Received in revised form 25 June 2013
Accepted 22 July 2013
Available online 27 July 2013
Keywords:
Periodontal disease
Diabetes mellitus
Porphyromonas gingivalis
Hepatic glycogenesis
SNAP26bPeriodontal diseases are common chronic inﬂammatory disorders that result in the destruction of tissues around
teeth. Many clinical studies suggest that periodontal diseases are risk factors for insulin resistance and diabetic
mellitus development. However, themolecularmechanisms bywhich periodontal diseases regulate the progress
of diabetes mellitus remain unknown. In this study, we investigated whether Porphyromonas gingivalis (P.g.), a
major pathogen of periodontal diseases, present in the oral cavity,moves to the liver and affects hepatic glycogen
synthesis. SNAP26b-tagged P.g. (SNAP-P.g.)was introduced into the oral cavity to induceperiodontal disease in 4-
week old female Balb/c mice. SNAP-P.g. was detected in the liver extracted from SNAP-P.g.-treated mice using
nested PCR analysis. High blood glucose levels tended to promote SNAP-P.g. translocation from the oral cavity
to the liver in mice. Periodic acid-Schiff staining suggested that hepatic glycogen synthesis decreased in SNAP-
P.g.-treatedmice. SNAP-P.g.was also internalized into the human hepatoma cell line HepG2, and this attenuated
the phosphorylation of insulin receptor substrate (IRS)-1, Akt and glycogen synthase kinase-3β induced by insu-
lin. Insulin-induced glycogen synthesis was suppressed by SNAP-P.g. in HepG2 cells. Our results suggest that P.g.
translocation from the oral cavity to the liver may contribute to the progress of diabetes mellitus by inﬂuencing
hepatic glycogenesis.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Periodontal diseases, including gingivitis and periodontitis, are com-
mon chronic inﬂammatory disorders caused by complexes of oral mi-
croorganisms including Porphyromonas gingivalis (P.g.). Progression of
periodontal disease results in the destruction of tissues around the
teeth. Because periodontal diseases evoke tooth loss in a large popula-
tion of adults, the prevention and management of periodontal disease
have an impact on health.
Diabetes mellitus is an increasingly common disorder, which has
negative effects on the eyes, kidneys, heart, blood vessels, and nerves
through blood glucose levels. Blood glucose levels are controlled by in-
sulin, which regulates both glucose absorption and glycogen synthesis
in the liver. Therefore, an inability to respond to insulin in the liver
cells leads to an increase in the blood glucose level in diabetes mellitus
patients. Glycogen synthase kinase-3 beta (GSK-3β) is a key enzyme
mediating insulin signaling via inhibition of glycogen synthase (GS),hima 770-8504, Japan. Tel./fax:
ights reserved.leading to a decrease in glycogen synthesis in the liver [1]. Brieﬂy, insu-
lin binds the insulin receptor (IR) and activated IR phosphorylates the
insulin receptor substrates (IRS)-1. On phosphorylation of the tyrosine
residues catalyzed by IR, IRS-1 initiates various down-stream signal
transduction and leads to phosphorylation and activation of the ser-
ine/threonine kinase Akt [2]. Activated Akt phosphorylates and thereby
inactivates GSK-3β. Inactive phosphorylated GSK-3β inhibition relieves
GS, leading to a decrease in glycogen synthesis. Indeed, GSK-3β inhibi-
tion increases glycogen synthesis and insulin sensitivity, indicating
that the Akt/GSK-3β signaling pathway plays an important role in regu-
lating the pathogenesis and progress of diabetes mellitus [3].
Diabetes mellitus has been reported to increase the severity of peri-
odontal diseases [4]. Conversely, recent studies have proposed that peri-
odontal diseases are risk factors for insulin resistance and diabetic
mellitus development. Taylor et al. showed that severe periodontitis ag-
gravated poor HbA1c control in patients with type 2 diabetes mellitus
[5]. Periodontal diseases increase the incidence of type 2 diabetes
mellitus among diabetes-free participants [6] and periodontal health is
associated with insulin resistance [7,8]. Furthermore, many reports
show that periodontal therapy improves diabetes mellitus. Non-
surgical periodontal treatments, such as scaling and root planning,
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reported that periodontal treatmentwith antibiotics has signiﬁcant pos-
itive effects on glycemic control [11].
Periodontal diseases affect host immune responses by elevating sys-
temic inﬂammatory factors including tumor necrosis factor-alpha
(TNF-α). These effects have been proposed as factors that promote the
pathogenesis of diabetes mellitus [12]. Local treatment with antibiotics
in the periodontal pocket and non-surgical periodontal treatment re-
duced the levels of circulating TNF-α and HbA1c in type 2 diabetes
mellitus patients [13,14]. These clinical studies suggest that periodontal
diseases are involved in the pathogenesis and progression of type 2
diabetes mellitus by controlling TNF-α; however, there are few
established experimental models for directly clarifying the correlation
between periodontal diseases and diabetes mellitus. Therefore, the mo-
lecular mechanisms underlying this association have not been well
characterized.
On the other hand, the translocation of oral microorganisms to
remote organs has been suggested to play an important role in disease
development. Many clinical reports have shown that P.g., a major path-
ogen of periodontal diseases, is frequently detected in various distant
organs such as the liver [15], cardiovascular tissue [16,17], cerebrospinal
ﬂuid [18], and tubal-ovarian locations [19]. Furthermore, P.g. is report-
edly able to invade intracellularly without signs of apoptosis and necro-
sis [20]. P.g. itself has many virulence factors such as collagenase,
aminopeptidase, and trypsin-like enzyme activity. The structural com-
ponents of P.g. including lipopolysaccharide (LPS) and ﬁmbriae, are
also known to trigger intracellular signaling events [21]. These observa-
tions suggest that the translocation of oral P.g. can elicit deleterious ef-
fects on cells in distant tissues.
In this study, we hypothesized that P.g. in the oral cavity moves to
the liver and is responsible for glycogen synthesis through Akt/GSK-
3β signaling in the liver cells. To test this hypothesis, we constructed
SNAP26b-tagged P.g. (SNAP-P.g.) and introduced it into the oral cavity
to induce periodontal disease in mice. We examined whether SNAP-
P.g. can move from the oral cavity to the liver tissue and affect hepatic
glycogen synthesis. SNAP-P.g. introduced into the oral cavity was de-
tected in the liver tissue. The high blood glucose levels tended to en-
hance SNAP-P.g. translocation. Glycogen accumulation in the liver
tissue tended to decrease in SNAP-P.g.-treatedmice. SNAP-P.g. internal-
ized and attenuated insulin-induced Akt/GSK-3β signaling in HepG2
cells, resulting in the suppression of glycogen synthesis. Our results
raise the possibility that P.g. in the oral cavity may contribute to the
pathogenesis of diabetes mellitus by affecting hepatic glycogenesis
through Akt/GSK-3β signaling.
2. Materials and methods
2.1. Bacterial cultures
P.g. ATCC33277 was cultured in Brain Heart Infusion (BD Bioscience,
Franklin Lakes, NJ) containing 0.5% yeast extract (BD Bioscience),
10 μg/mL hemin (Wako Chemicals, Osaka, Japan) and 1 μg/mL 2-
methyl-1,4-naphthoquinone (vitamin K3) (Tokyokasei, Tokyo, Japan)
in an anaerobic jar at 37 °C. For the culture of SNAP-P.g., 5 μg/mL tetracy-
cline was added to the medium described above.
2.2. Cell culture and treatment with P.g. preparations
The human hepatocyte carcinoma cell line HepG2 was cultured in
Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented with 10%
FBS at 37 °C under a humidiﬁed atmosphere of 5% CO2. After reaching
70–80% conﬂuence in plastic dishes, cells were used for experiments.
For treatment with P.g., the growth medium was replaced with 2% FBS
inDMEMovernight and then the cellswere incubatedwith P.g. at amul-
tiplicity of infection (MOI) of 100 for the desired period.2.3. Establishment of SNAP-P.g.
SNAP-P.g. was constructed by transforming P. gingivalis ATCC33277
with a shuttle vector containing the SNAP26b gene cloned under the
control of the P. gingivalis endogenous trxB promoter into P. gingivalis
ATCC33277, as described previously [22] with modiﬁcations. The sche-
ma of SNAP-P.g. construction is shown in Supplementary Fig. 1. Please
refer to the legend of Supplementary Fig. 1 for details on the cloning
procedure. Information on the microorganism strain, plasmids, and
primers used in this study is provided in Supplementary Tables 1 and
2. Fluorescent microscopic detection by labeling with SNAP-Cell® TMR
Star (New England Biolabs, NEB, Ipswich, MA), a cell-permeable sub-
strate, was performed to conﬁrm the expression of SNAP26 in SNAP-
P.g. (Supplementary Fig. 2).
2.4. Animal and oral infection
All experiments were humanely conducted under the regulation and
permission of the Animal Care and Use Committee of the University of
Tokushima, Tokushima, Japan. Four-week old female Balb/c mice were
orally infectedwith SNAP-P.g. as describedpreviously [23]withmodiﬁca-
tions. Brieﬂy, mice received water with 1 mg/mL kanamycin ad libitum
for 7 days, followed by no antibiotics for 3 days. Then, mice were placed
on the high-fat diet; Quick Fat (15.3% fat, 424.5 kcal/100 g; Japan CLEA,
Tokyo, Japan) and were infected with 1.0 × 109 CFU of SNAP-P.g. in
100 μL PBS with 2% carboxymethylcellulose for 3 weeks at 3-day inter-
vals. Control group received carboxymethylcellulose without SNAP-P.g.
After 3 weeks of infection, the mice were injected twice with
streptozotocin (0.1 mg/g body weight i.p.) for 2 weeks to induce insulin
deﬁciency. Fasting blood glucose was measured by GLUCOCARD™
MyDIA using the manufacturer's instructions (Arkray, Tokyo, Japan).
2.5. Microcomputed tomography (μCT) analysis of bone
Bonemineral density (g/cm2)was determined byDual Energy X-ray
Absorptiometry (DXA). After euthanizing the animals, mandibulae
were removed and dissected from soft tissue. The bones were analyzed
by a μCT system (Latheta LCT-200, Aloka, Tokyo, Japan) and 2D images
were reconstructed into 3D images with Avizo 6.1 software (VSG Inc.,
Burlington, MA).
2.6. Detection of P.g. from the gingiva and liver tissue by PCR
Gingiva and liver tissues frommice were homogenized with 100 μL
PBS. An aliquot of the solution (5 μL) was applied to an FTA® card (GE
Healthcare, Buckinghamshire, UK). After drying, paper disks were
made from each card using Micro-Punches, and transferred to separate
tubes. Each diskwaswashedwith DNase-free H2O, dried, and subjected
to PCR. The PCR reaction was performed in 50 μL using 1.25 U
MightyAmp® DNA polymerase (Takara Bio, Kyoto, Japan) containing
1× PCR buffer, 2 mM MgCl2, 0.4 mM dNTP mixture, and 0.5 mM
primers. The 1st PCR protocol was 98 °C for 2 min followed by 33 cycles
of denaturation at 98 °C for 10 s, annealing at 60 °C for 15 s and elonga-
tion at 68 °C for 30 s. Then, using 1 μL of the 1st PCRproduct, nested PCR
was performed using the same protocols as above. Primer sequences
were as follows: SNAP26b (for 1st PCR, product size; 587 bp): forward,
5′-GGCCGAATTCATGGACAAAGATTGCGAAATG-3′; reverse, 5′-CCGGGG
ATCCTGGCGCGCCTATACC-3′ and SNAP26b (for nested PCR, product
size; 381 bp): forward, 5′-GCCTGCATGAAATTAAACTGCT-3′; reverse,
5′-CACCGCTAGAGCTAACCACAC-3′.
2.7. Invasion assay
HepG2 cells were cultured to 70–80% conﬂuence in plastic dishes
and then incubated for 12 h in 2% FBS DMEM. SNAP-P.g. (100 MOI)
was reacted with HepG2 cells for the indicated periods. External
Fig. 1. SNAP-P.g. was detected in the gingiva and liver tissue from mice with periodontal disease. (A) Nested PCR analysis of SNAP26b expression in the gingiva from non-treated mice
(cont) and SNAP-P.g. treatedmice (P.g.). SNAP-P.g.was used as a template for PCR as a positive control (C). The arrow indicates the size of the PCR product (381 bp).M,molecular marker.
(B) μCT 3-dimensional reconstruction images of mandibula frommice treated with (P.g.) or without (cont) SNAP-P.g. (C) Fasting blood glucose in mice treated without (cont; n = 5) or
with SNAP-P.g.-treated mice (P.g.; n = 5) and SNAP-P.g.-plus-streptozotocin-treatedmice (P.g. + STZ; n = 6). The box and whisker plots present medians, 25th and 75th quartiles, and
the complete data range. *p b 0.05 compared with mice treated without SNAP-P.g.; Mann–Whitney U-test. Mean ± SD of each group were 66.8 ± 11.9 (cont), 81.8 ± 9.9 (P.g.) and
136.8 ± 66.9 (P.g. + STZ). (D) Nested PCR analysis of SNAP26b expression in the livers from SNAP-P.g.-treated mice (SNAP-P.g.) and SNAP-P.g.-plus-streptozotocin-treated mice
(SNAP-P.g. + STZ). C, positive control; M, molecular marker.
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washing twice with PBS. External adherent SNAP-P.g. was killed by
treatment with 200 μg/mL metronidazole (Sigma) for 1 h. Subse-
quently, the cells were washed twice with PBS and internal bacteria
were released by lysing cells in sterile distilled water for 15 min. The
lysates were plated on blood agar and cultured anaerobically for 7 to
10 days. Invasion was expressed as the number of colonies after
culture.
2.8. Transmission electron microscopy (TEM)
HepG2 cells were grown on 3-dimensional substrates (3-D) [24] and
ﬁxed in 2% paraformaldehyde and 2% glutaraldehyde in 0.1 M sodium
cacodylate buffer (pH 7.2) for 12 h at 4 °C. Samples were then rinsed
in 0.1 M cacodylate buffer and postﬁxed in 1% osmium tetroxide for
2 h at room temperature, then dehydrated in 50, 70, 80, 95 and 100%
ethanol for 10 min, 3 times for each ethanol change. The ﬁxed cellswere cut into smaller pieces (approximately 20 mm2) and embedded
in resin (Quetol 812, Wako Chemicals) for 48 h at 60 °C. Solidiﬁed
ultra-thin sections were produced, stained with uranyl acetate lead to
citrate, and observed under an H7650 TEM (Hitachi, Tokyo, Japan). For
immunoelectron microscopic analysis, cells grown on 3-D substrates
were ﬁxed in 4% paraformaldehyde in 0.1 M sodium phosphate buffer
(PB), pH 7.2 for 12 h at 4 °C. After washing with the same buffer,
samples were dehydrated as described above and embedded in resin
(LR White Medium, EMS, Hatﬁeld, PA, USA). Ultra-thin sections of the
solidiﬁed samples were blocked for 30 min with PB containing 5%
normal goat serum and then incubated overnight at 4 °C with anti-
SNAP-tag® rabbit polyclonal antibody (NEB) in the blocking solution
(1/1000 dilution). Then, the sections were exposed for 60 min at
room temperature to colloidal gold-conjugated goat anti-rabbit IgG
(COSMO BIO, Tokyo, Japan) in Tris-buffered saline (TBS; 1/50 dilution).
After ﬁxing with 2% glutaraldehyde, the sections were observed under
TEM.
Fig. 2.Hepatic glycogenwas decreased in SNAP-P.g.-treatedmice. (A) PAS staining of the liver with (+) or without (−) incubation with Schiff's reagent. (B) PAS staining of the liver from
SNAP-P.g.-treated (SNAP-P.g.;middle panel) and SNAP-P.g.-plus-streptozotocin-treatedmice (SNAP-P.g. + STZ; lowerpanel). The upper panel presents the liver fromSNAP-P.g.-untreated
mice (−). The sample number indicates the same number of mice as shown in Fig. 1D.
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Liver tissues from mice were embedded in OCT compound. The
frozen-embedded specimens were cut at 4 μm thickness and subjected
to PAS staining. Theywere treatedwith 0.5% periodic acid for 5 min and
washed twice in de-ionized water for 1 min. Then, theywere incubated
in Schiff's reagent (Wako Chemicals) at room temperature for 15 min
and washed 3 times with sodium pyrosulﬁte for 3 min. After washing
with water for 3 min, they were counter-stained for 1 min using
Mayer's hematoxylin. HepG2 cells were ﬁxed with 4.0% formalin for
1 h, treated with 1% periodic acid for 15 min and then treated with
Schiff's reagent for 1 h in the dark. The samples were mounted and ex-
amined under a microscope.
2.10. SDS-PAGE and western blot analysis
Cells were washed with PBS and proteins were scraped into TN lysis
buffer (50 mM Tris [pH 8.0], 150 mMNaCl, 0.1% NP-40) in the presence
of protease inhibitors (4 μg/mL aprotinin, 1 μg/mL leupeptin, 0.2 mM
PMSF). The protein extracts were subjected to immunoblotting
according to the protocol described previously [25]. Antibodies against
IRS-1 (D23G12), GSK-3β (27C10), phosphor-GSK-3β (Ser9), phosphor-
Akt (Ser473) and phosphor-GS (Ser641) were obtained from Cell
Signaling Technology (Danvers, MA, USA). The β-actin antibody was
obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and
the SNAP-tag® rabbit polyclonal antibody was obtained from New
England Biolabs. The phosphor-IRS-1 (Tyr612) was obtained from
Invitrogen.
2.11. Statistical analysis
All data are expressed asmeans ± SD and aminimum of 3 indepen-
dent experimentswere performed for each assay. The Student's t-test or
Mann–Whitney U test was used for statistical analysis.3. Results
3.1. SNAP26b was detected from the liver in orally SNAP-P.g.-infected mice
After oral infectionwith SNAP-P.g. for 30 days, the gingiva, liver, and
mandibula were isolated from the mice. First, we examined whether
SNAP-P.g. infection induced periodontal diseases in themice. The results
of nested PCR analysis showed that SNAP26b was detected in gingival
tissue from SNAP-P.g.-treated mice, but not the untreated mice
(Fig. 1A, left panel). As a positive control, SNAP-P.g. was used for the
nested PCR reaction (Fig. 1A, right panel). The distance from the
cement-enamel junction to the mandibular bone crest was increased
in SNAP-P.g.-treated mice compared to control mice (Fig. 1B).
Next, we treated mice intraperitoneally with streptozotocin at a con-
centration of 0.1 mg/g bodyweight in order to induce high blood glucose.
Fasting blood glucosewas signiﬁcantly increased by streptozotocin treat-
ment inmice (Fig. 1C). We examinedwhether SNAP26b is present in the
liver tissue from mice orally infected with SNAP-P.g. as determined by
nested PCR analysis using SNAP26b-speciﬁc primers. SNAP26b was de-
tected in the liver of SNAP-P.g.-treated mice (Fig. 1D). In streptozotocin-
treated mice that were also infected with SNAP-P.g., SNAP26b seemed
to be detected at higher frequency than in SNAP-P.g.-treated mice alone
(Fig. 1D). The PCR product was extracted from the gel and it was con-
ﬁrmed that its sequence was homologous to that of SNAP26b (Supple-
mentary Fig. 3).
3.2. Glycogen synthesis in the liver was reduced in SNAP-P.g.-treated mice
Due to the observation that SNAP-P.g. introduced in the oral cavity
moved to the liver tissue, we examined whether glycogen synthesis
was changed in the livers from SNAP-P.g.-treated mice. Frozen sections
of the liver samples were subjected to periodic acid-Schiff (PAS) stain-
ing to detect glycogen deposition. Treatment with Schiff's reagent
showed PAS-positive glycogen deposition, whereas positivity was not
Fig. 3. SNAP-P.g. internalizes into HepG2 cells in vitro. (A) Images of transmission electronmicroscopy of SNAP-P.g.-treated HepG2 cells. a, c; Lowermagniﬁcation images of cells (×1000).
b, d; Highermagniﬁcation images of a and c (×4000). White arrowheads indicate SNAP-P.g.; white arrows indicate vesicles bound by doublemembranes. e; The images of cells following
immunohistostaining using an SNAP26b-speciﬁc antibody. (B), (C) Western blot analysis of HepG2 cells treated with SNAP-P.g. at an MOI of 100 for 0, 2, and 6 h (B), and for 6 h in the
presence of glucose or mannitol (C). The arrow indicates SNAP26b-speciﬁc bands; ns, non-speciﬁc bands (left panel). Invasion assay of SNAP-P.g. in HepG2 cells (right panel, n = 4).
Values represent the mean ± S.E.M. of each number of colonies. **p b 0.01 compared to HepG2 cells cultured without SNAP-P.g.
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shows the representative staining patterns, in which deposition of gly-
cogen was detected in the livers from SNAP-P.g.-treated mice with or
without streptozotocin injection. The numbers in the pictures indicate
the same samples as shown in Fig. 1C. Signiﬁcant (#1, #2, #3, #7 and
#9) ormild reduction (#4, #10 and#11) in glycogen depositionwas ob-
served in the livers of SNAP-P.g.-treatedmice comparedwith SNAP-P.g.-
untreated mice.
3.3. SNAP-P.g. internalized to HepG2 cells
In order to investigate the molecular mechanisms by which SNAP-
P.g. suppressed glycogen synthesis in the liver, we used a human hepa-
toma cell line, HepG2. SNAP-P.g. was found within the cytoplasm inHepG2 cells (Fig. 3A, a–d). Some of the SNAP-P.g.was embeddedwithin
vesicle structures bound by double membranes (Fig. 3A, b). We con-
ﬁrmed oral infection by SNAP-P.g. by immunohistochemical staining
using an SNAP26b-speciﬁc antibody (Fig. 3A, e). Furthermore, the exis-
tence of SNAP-P.g. in HepG2 cellswas examined bywestern blot. The in-
tensity of the band corresponding to SNAP26b increased in a time-
dependentmanner up to 6 h (Fig. 3B, left toppanel). Theβ-actin protein
level, used as an internal control, was unchanged in each sample
(Fig. 3B, left bottom panel). To clarify whether the internalized SNAP-
P.g.was alive or dead, an invasion assay was performed. After infection
with SNAP-P.g., the cells were disrupted and aliquots of the cell lysate
were plated on blood agar. The plates were incubated for 7–10 days;
the number of colonies indicated live internalized SNAP-P.g. Consistent
with the results of the western blot for SNAP26b, the number of SNAP-
Fig. 4. SNAP-P.g. inhibited insulin-induced Akt/GSK-3β signaling in HepG2 cells. Western blot analysis for the expression of proteins that regulate Akt/GSK-3β signaling in HepG2 cells.
HepG2 cells were treated with 0–100 nM insulin for 30 min (A), 100 nM insulin for 0 to 60 min (B), or 100 nM insulin for 30 min in various concentrations of SNAP-P.g.with or without
50 mM glucose (C). The arrow indicates SNAP26b-speciﬁc bands; ns, non-speciﬁc bands.
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2 h and 6 h (Fig. 3B). To assess the effect of glucose on SNAP-P.g. inter-
nalization,western blot analysis and the invasion assaywere performed
in the presence of glucose. Both analyses showed that glucose treatment
did not change the levels of SNAP-P.g. internalization (Fig. 3C). Mannitol
was also used to investigate the inﬂuence of osmolarity. The results of
the invasion assay showed that glucose and mannitol did not affect
SNAP-P.g. internalization into HepG2 cells.
3.4. SNAP-P.g. inhibited insulin-induced Akt/GSK-3β signaling pathway in
HepG2 cells
To clarify the molecular mechanisms by which SNAP-P.g. regulates
hepatic glucose metabolism, we examined the effects of SNAP-P.g. on
insulin-induced Akt/GSK-3β signaling. Treatment with insulin at vari-
able concentrations (0–100 nM) increased IRS-1 phosphorylation at ty-
rosine 612 as well as the total IRS-1 protein level. The phosphorylation
of Akt at serine 473 was increased by insulin treatment in a dose-
dependent manner (Fig. 4A). IRS-1 phosphorylation at tyrosine 941
and Akt phosphorylation at threonine 308 did not change upon insulin
treatment (data not shown). Treatment with 100 nM insulin also phos-
phorylated GSK-3β at serine 9 (Fig. 4A). Next, HepG2 cells were treatedwith 100 nM insulin for the indicated periods and the phosphorylation
status of IRS-1 and Akt/GSK-3β was determined. Both IRS-1 and Akt/
GSK-3βwere phosphorylated at 5 min up to 60 min after the treatment
of 100 nMinsulin (Fig. 4B).We examined the IRS-1 andAkt/GSK-3β sig-
naling following infectionwith various concentrations of SNAP-P.g.with
or without glucose. Consistent with the results in Fig. 3, SNAP-P.g. inter-
nalized into HepG2 cells at 6 h after infection in dose dependent man-
ner. Infection with SNAP-P.g. at a concentration of 50 and 100 MOI
decreased the rate of IRS-1 and Akt/GSK-3β phosphorylation induced
by insulin; however, glucose addition did not affect the phosphorylation
status (Fig. 4C). SNAP-P.g. infection did not change the phosphorylation
of IRS-1 at serine 636/639 and serine 312,which have been suggested to
impair the insulin signaling regulated by TNF-α (data not shown).
3.5. SNAP-P.g. suppressed glycogen synthase and glycogen synthesis in
HepG2 cells
To investigate whether SNAP-P.g. affects glycogen synthesis in
HepG2 cells, we treated cells with insulin for 60 min and then detected
the phosphorylation of GS at serine 641 by western blotting. As
expected, the level of phosphorylated GS was reduced by insulin treat-
ment (Fig. 5A, lane 2). SNAP-P.g. recovered the level of phosphorylated
Fig. 5. SNAP-P.g. suppresses glycogen synthase and glycogen synthesis inHepG2 cells. (A)Western blot analysis for glycogen synthase phosphorylation (pGS) at serine 641 in HepG2 cells.
Arrow indicates SNAP26b-speciﬁc bands; ns, non-speciﬁc bands. (B) PAS staining in insulin-treated HepG2 cells with orwithout SNAP-P.g. Top panels show lowermagniﬁcation images of
cells (×4). Bottom panels are higher magniﬁcation images of the same cells as in the top panels (×20).
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ther examined whether SNAP-P.g. affects glycogen synthesis in HepG2
cells. After treatment of insulin with or without SNAP-P.g. for the indi-
cated periods, glycogen accumulation was detected by PAS staining. In-
sulin treatment for 20 h, but not 5 h, increased glycogen deposition in
HepG2 cells. SNAP-P.g. drastically inhibited this insulin-induced in-
crease in glycogen deposition (Fig. 5B).
4. Discussion
The main ﬁnding in this study was that SNAP-P.g. translocated
from the oral cavity to the liver tissue in mice and this translocation
appeared higher in mice with high blood glucose level. Another im-
portant ﬁnding was that glycogen synthesis in the liver tended to de-
crease in orally SNAP-P.g.-infected mice. In agreement with the
results of animal studies, SNAP-P.g. internalized into HepG2 cells
and then inhibited glycogen synthesis by affecting Akt/GSK-3β sig-
naling in vitro.
In the present study, we labeled P.g. with SNAP26b instead of ﬂuo-
rescent proteins such as GFP in order to speciﬁcally and clearly trace
P.g. translocation. Because P.g. is an anaerobic bacteria, oxygen inhibits
the proliferation of P.g. Fluorescent proteins, which require oxygen to
emit ﬂuorescence, were therefore not useful as protein tags in this
study. The SNAP26b protein was successfully expressed in P.g.
ATCC33277 under anaerobic conditions, and was effective in detecting
P.g. localization both in vivo and in vitro. Introduction of SNAP-P.g.
into the oral cavity induced gingival infection and horizontal boneloss, indicating that SNAP-P.g. functions as a pathogen of periodontal
disease in this experimental model.
In vitro, we showed that living SNAP-P.g. internalized into
HepG2 cells. SNAP-P.g. was embedded in vesicle structures
bound by double membranes, suggesting that endocytosis might
be implicated in SNAP-P.g. internalization. Internalized SNAP-P.g.
decreased insulin-induced glycogenesis through the inhibition of
Akt/GSK-3β signaling and GS phosphorylation. These results
in vitro suggest that P.g. internalizes into hepatocytes and pro-
motes the pathogenesis of diabetes mellitus by increasing blood
glucose levels if oral P.g. translocates to the liver tissue under cer-
tain conditions.
On the other hand, the following questions remain to be clariﬁed in
thepresent study. First, howdoes P.g. in the oral cavity translocate to the
liver tissue and stay there? One possible answer is that P.g. invades the
vascular endothelial cells in periodontal tissue and reaches the liver tis-
sue through the blood circulation. P.g. is known to frequently invade the
blood circulation from periodontal tissues [26] and hyperglycemia, a
condition of high blood glucose in diabetes, induces cardiovascular dis-
eases by causingmicro- andmacrovascular complications [27]. Our data
showed that treatment with streptozotocin in addition to SNAP-P.g. in-
creased the fasting blood glucose concentration and high blood glucose
levels tended to promote the translocation of SNAP-P.g. to the liver tis-
sue. Thus, it is likely that vascular endothelial cells injured by hypergly-
cemia could facilitate the invasion of P.g. into the blood circulation,
resulting in the higher detection frequency of P.g. in the liver tissue in
streptozotocin-treated mice. Further studies are needed to investigate
Fig. 6. Proposed model of P.g.-regulated glycogen synthesis in the liver. P.g. in the oral
cavity moves to the liver and down-regulates glycogen synthesis by inhibiting insulin-
induced Akt/GSK-3β signaling in hepatocytes. See text for details.
2042 M. Ishikawa et al. / Biochimica et Biophysica Acta 1832 (2013) 2035–2043how the blood glucose level inﬂuences the ability of P.g. to invade endo-
thelial cells and blood circulation.
It is also conceivable that abnormal lipid metabolism promotes the
accumulation of P.g. in the liver tissue, leading to an increase in its detec-
tion frequency in streptozotocin-treatedmice. Recently, it was reported
that P.g. was detected in the livers of patients with non-alcoholic fatty
liver disease (NAFLD), including non-alcholic fatty liver and non-
alcholic steatohepatitis (NASH) [15,28]. In NAFLD, excessive delivery
of free fatty acids and imbalance in lipid synthesis cause increased fat
accumulation in the liver. Diabetes mellitus and obesity have been
known to be involved in the pathogenesis of NAFLD [29]. The detection
frequency of P.g. in the liver was signiﬁcantly higher in NAFLD patients
than in healthy subjects. Moreover, a higher frequency of diabetes
mellitus has been noted in P.g.-positive NASH patients [15]. Dental in-
fection with P.g. induced fatty liver in mice fed a high-fat diet, but not
those on a normal diet. In these mice with fatty liver induced by a
high-fat diet, P.g. was detected in hepatocytes by immunohistochemis-
try [28]. Based on these reports, it is likely that P.g. has a tendency to ac-
cumulate in fatty liver, which has abnormalities in lipid metabolisms
and diabetes mellitus. In the present study, a high-fat diet was used to
accelerate the effects of streptozotocin. Therefore, changes in hepatic
fattymetabolism induced by a high-fat dietmay contribute to increased
P.g. accumulation in the liver tissue, and hyperglycemia is probably as-
sociated with this process. To validate these possibilities, changes in cir-
culating triglyceride concentrations and the expression of enzymes
involved in triglyceride synthesis must be assessed in future studies.
The second question is how translocated P.g. inﬂuences the pathogen-
esis and progress of diabetesmellitus. Our data clearly demonstrated that
SNAP-P.g. internalized to HepG2 cells and inhibited the insulin-induced
Akt/GSK-3β signaling, resulting in a decrease in hepatic glycogenesis
in vitro. In vivo, suppression of glycogen deposition in the liver was ob-
served in SNAP-P.g.-treated mice with and without streptozotocin-
treatment (Fig. 2B). Based on these observations, it is possible that
translocated-SNAP-P.g. could itself affect hepatic glycogen synthesis, at
least in part. On the other hand, various levels of glycogen synthesis
were observed in SNAP-P.g.-treated mice: for example, both strong inhi-
bition (#1, #2, #3, #7 and #9) and mild inhibition (#4, #10 and #11)were observed (Fig. 2B). Furthermore, glycogen deposition was also de-
creased in samples that showed undetectable levels of SNAP-P.g. in the
liver by nested PCR analysis (#1, #4 and#10 in Figs. 1C and2B). Although
the reasons for these discrepancies are still unknown, themechanism in-
volved in the regulation of hepatic glycogenesis appears to be something
other than direct effect of translocated-SNAP-P.g. One possible candidate
is the upregulation of inﬂammatory cytokines such as TNF-α, because
TNF-α increases upon P.g. treatment and affects insulin resistance in an-
imal models [30,31]. We, therefore, investigated the expression of in-
ﬂammatory cytokines in the liver of SNAP-P.g.-treated mice. The
expressions of IL-1β and IL-6 mRNA in the liver were not changed by in-
fectionwith SNAP-P.g.On the other hand, the expression of TNF-αmRNA
was signiﬁcantly higher in the liver of SNAP-P.g.-plus-streptozotocin-
treatedmice (STZ) than in that of the control mice (cont) (Supplementa-
ry Fig. 4). We also investigated whether TNF-α is involved in glycogen
synthesis regulated by SNAP-P.g. in HepG2 cells. Treatment with SNAP-
P.g. signiﬁcantly increased TNF-α mRNA expression (Supplementary
Fig. 5A). We examined whether SNAP-P.g.-induced TNF-α affects Akt
and GSK-3β phosphorylation in para- or autocrine fashion. However,
treatment with human recombinant TNF-α did not inhibit insulin-
induced Akt and GSK-3β phosphorylation (Supplementary Fig. 5B).
These results suggest that another factor, in addition to TNF-α, is also im-
portant for the glycogen synthesis regulated by SNAP-P.g. in the present
model.
Furthermore, to verify the additional mechanisms by which SNAP-P.
gingivalis inhibits glycogen accumulation, we investigated whether the
infection by SNAP-P. gingivalis affects glycogen synthesis and/or glyco-
genolysis in HepG2 cells. In Fig. 5, we showed that SNAP-P. gingivalis in-
creased the inactive form of glycogen synthase, an enzyme which
increases glycogen synthesis. We further examined the effect of SNAP-
P.g. on the expression of glycogen phosphorylase (PYGL), which cata-
lyzes the key step of glycogen degradation. Treatment with insulin for
24 h decreased the PYGL mRNA expression level (Supplementary
Fig. 6A). The expression of PYGL mRNA inhibited by insulin was im-
proved by SNAP-P.g. infection. Moreover, SNAP-P.g. infection itself in-
creased the expression of PYGL mRNA (Supplementary Fig. 6B). These
results raised the possibility that the infection of SNAP-P.g. suppresses
glycogen accumulation in the liver by affecting both glycogen synthesis
and glycogenolysis. Further studies are needed to verify the mecha-
nisms by which SNAP-P.g. inhibits glycogen accumulation in the liver.
5. Conclusion
Wedemonstrate that P.g. introduced into the oral cavity can translo-
cate to the liver tissue and internalize into hepatocytes. Normally, in he-
patocytes, insulin stimulation leads to an increase in IRS-1 andAkt/GSK-
3β phosphorylation, followed by GS activation. Activated GS causes an
increase in glycogen synthesis and blood glucose is maintained at low
levels. The present study suggests that the presence of P.g. in hepato-
cytes inhibits this insulin signaling and results in decreased glycogen
synthesis (Fig. 6). Our ﬁndings provide further understanding of the
molecular mechanisms by which periodontal diseases progress the
pathogenesis of diabetes mellitus, and we propose that reduction of
oral bacteria by periodontal therapy might be important for the man-
agement of diabetes mellitus.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2013.07.012.
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